Additionally, Medicaid coverage of GLP-1 medications for obesity varies across states, leaving many patients ineligible for coverage depending on where they live
Whether enough people fall into the second bucket, and whether WW can serve them profitably, is the whole bet.
Every patient begins at the lowest therapeutic dose (0.25 mg weekly) and only advances every four weeks if side effects remain mild and weight loss progresses
Yes, nausea is the most common side effect, affecting 16-44% of patients depending on the formulation
Potential warning signs include: Noticeable weakness Loss of muscle tone Dizziness Persistent fatigue Hair shedding Feeling cold all the time Constipation Poor workout recovery Low protein intake Very low appetite Reduced balance or stamina Rapid weight loss without strength training These symptoms do not always mean muscle loss is occurring, but they should prompt a conversation with a qualified medical provider
Disease-Modifying Anti-Rheumatic Drugs (DMARDs) DMARDs are a mainstay in RA treatment
